Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myogen (MYOG) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (16)	2/13/2006 12:46:10 PM
From: tuck	Read Replies (1) \| Respond to of 50

Well, it's a guess; the next dosage up is 10mg or twice the dose. Isn't that where we started to see the LFT issues? Do we have data on the LFT parameter longer than 12 weeks in any population? The company has spoken of long exposure by 300 patients: investor.myogen.com They even speak of a "mean dosage of 7.5mg" but how meaningful is that when there is no such dose? investor.myogen.com Where are the long term LFT numbers? Not in the PRs or ATS abstract. Thanks for any help. I guess we'll find out with ARIES 1, which will have the higher dose populations, in a few months. Cheers, Tuck